Skip to main content
AMCP Nexus 2024 Main banner
Back

Keynote

(K3) Oncology Pipeline 2024: Innovation and Trends

Thursday, October 17, 2024
10:30 AM – 11:45 AM PT
Location: 121
CPE
ACPE UAN:0233-0000-24-063-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
This activity is supported by an independent medical education grant from Coherus Biosciences, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Replimune Group, Inc.

The oncology pipeline has continually expanded over the past decade, currently representing 38% of the agents in active development. Global spending on cancer medicine was $196 billion in 2022 and is expected to exceed $375 billion by 2027. As the number of treatments and the amount spent continue to increase, it is important for stakeholders to be aware of the latest therapies that will impact their practice. This session will cover key agents recently approved by the FDA or in late-stage development, focusing on novel mechanisms of action. The potential impact on current standards of care and what this may mean for payers will be discussed.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Identify recently approved and upcoming approvals of high-impact oncology specialty drugs for solid and hematologic malignancies.
  2. Differentiate the mechanisms of action, indications, safety, and efficacy of newly approved and emerging oncology specialty medications.
  3. Assess the impact of new and emerging approvals of oncology specialty medications on cost considerations, contracting, benefit formularies, and other managed care processes.